Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes, today announced that it entered into a multi-target drug discovery agreement with Janssen Pharmaceutica N.V. (Janssen).
He is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration was facilitated by Johnson & Johnson Innovation LLC.
Under the terms of the agreement, Insilico Medicine will design small molecule hits with the defined properties for several targets nominated by Janssen and to receive upfront and milestone payments. Insilico Medicine will demonstrate the discovery process and detailed platform capabilities.
Since 2015 Insilico Medicine pioneered the field of generative adversarial networks and reinforcement learning for generative chemistry and generative biology and published multiple research publications and patents in the area including proof-of-concept studies with experimental validation.
In 2020 it unveiled the Chemistry42 generative chemistry operating system and made first on-site deployments with the big pharmaceutical companies and drug discovery partnerships.
We are very happy to collaborate with Janssen, one of the leading and most innovative companies in the field of drug discovery. Since 2019 Insilico Medicine has been a resident of Johnson & Johnson Innovation - JLABS which facilitated closer communication with the scientists at Janssen and other companies in the ecosystem and we see this collaboration as a 'graduation' from JLABS."
Alex Zhavoronkov, PhD, Founder, and CEO, Insilico Medicine
Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery